Ampicillin Injectable Solution Recalled Due to Lack of Sterility Assurance
Sentara Infusion Services is recalling Ampicillin 12GM in NS 600M injectable solution due to lack of sterility assurance. The affected product was dispensed nationwide; patients should contact their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of an injectable medication with potential sterility failure, which poses a risk of infection from non-sterile administration. Although no illnesses or injuries have been reported in the source material, the theoretical hazard associated with loss of sterility assurance in injectable drugs justifies a High severity rating.
Plain-English summary
Sentara Infusion Services is recalling Ampicillin 12GM in NS 600M injectable solution (19 bags) due to lack of sterility assurance. The product is used with a Curlin pump for intravenous administration.
The recall affects patients nationwide who received this medication. The affected product has a beyond-use date of December 25–29, 2022.
Patients who received this product should contact their healthcare provider or pharmacist immediately to discuss the recall and any potential next steps. Healthcare providers should not dispense any remaining affected product.
The recalled product
- Product
- AMPICILLIN 12GM IN NS 600M, used with a Curlin pump, Sentara Home Infusion Pharmacy Services, 535 Independence Pkwy, Ste 300, Chesapeake, VA 23320,
- Manufacturer
- Sentara Infusion Services
- Category
- Drug — Injectable / Antibiotic
- Hazard
- sterility-failure
- contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Beyond Use date: December 25 - December 29
- 2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27